Vendeur : BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Allemagne
Taschenbuch. Etat : Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Radium-223 dichloride (Ra-223) is an alpha particle-emitting radiopharmaceutical whose licensed indication in patients with castration-resistant prostate cancer with bone metastases (CRPCm) was modified in June 2018, due to the appearance of drug-drug interactions with common drugs in CRPCm such as abiraterone and prednisone/prednisolone. Thus, it was restricted to use in monotherapy or combination with luteinizing hormone-releasing hormone analogues, becoming third-line treatment in patients with CRPCm, for which evidence on its effectiveness and safety in this new context is lacking. 60 pp. Englisch. N° de réf. du vendeur 9786206581642
Quantité disponible : 2 disponible(s)
Vendeur : AHA-BUCH GmbH, Einbeck, Allemagne
Taschenbuch. Etat : Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Radium-223 dichloride (Ra-223) is an alpha particle-emitting radiopharmaceutical whose licensed indication in patients with castration-resistant prostate cancer with bone metastases (CRPCm) was modified in June 2018, due to the appearance of drug-drug interactions with common drugs in CRPCm such as abiraterone and prednisone/prednisolone. Thus, it was restricted to use in monotherapy or combination with luteinizing hormone-releasing hormone analogues, becoming third-line treatment in patients with CRPCm, for which evidence on its effectiveness and safety in this new context is lacking. N° de réf. du vendeur 9786206581642
Quantité disponible : 1 disponible(s)
Vendeur : moluna, Greven, Allemagne
Etat : New. N° de réf. du vendeur 1188787031
Quantité disponible : Plus de 20 disponibles
Vendeur : buchversandmimpf2000, Emtmannsberg, BAYE, Allemagne
Taschenbuch. Etat : Neu. This item is printed on demand - Print on Demand Titel. Neuware -Radium-223 dichloride (Ra-223) is an alpha particle-emitting radiopharmaceutical whose licensed indication in patients with castration-resistant prostate cancer with bone metastases (CRPCm) was modified in June 2018, due to the appearance of drug-drug interactions with common drugs in CRPCm such as abiraterone and prednisone/prednisolone. Thus, it was restricted to use in monotherapy or combination with luteinizing hormone-releasing hormone analogues, becoming third-line treatment in patients with CRPCm, for which evidence on its effectiveness and safety in this new context is lacking.VDM Verlag, Dudweiler Landstraße 99, 66123 Saarbrücken 60 pp. Englisch. N° de réf. du vendeur 9786206581642
Quantité disponible : 1 disponible(s)